Search

TG Therapeutics Inc

Затворен

СекторЗдравеопазване

55.79 -1.24

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

55.66

Максимум

56.25

Ключови измерители

By Trading Economics

Приходи

7.8M

28M

Продажби

35M

240M

P/E

Средно за сектора

19.818

56.659

EPS

0.05

Марж на печалбата

11.466

Служители

399

EBITDA

-6.4M

22M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+23.56% upside

Дивиденти

By Acuity

Следващи печалби

2.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.2B

8.3B

Предишно отваряне

57.03

Предишно затваряне

55.79

Настроения в новините

By Acuity

50%

50%

132 / 339 Класиране в Healthcare

TG Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.09.2026 г., 20:07 ч. UTC

Social Media

TG Therapeutics Inc is declining amid increased selling pressure in risk assets following a strong jobs report raising monetary policy concerns.

3.09.2026 г., 20:07 ч. UTC

News
Social Media

TG Therapeutics will participate in the Cantor Global Healthcare Conference. Shares are lower today, despite earlier gains and positive sentiment surrounding the company.

2.09.2026 г., 20:02 ч. UTC

Social Media

TG Therapeutics shares are higher as HC Wainwright reiterates its Buy rating. Social media valuations suggest a price range of $78 to $85 per share.

1.09.2026 г., 19:54 ч. UTC

News
Social Media

TG Therapeutics shares are rising as H.C. Wainwright maintains a Buy rating and sets a price target of $78, indicating significant upside potential.

31.08.2026 г., 22:16 ч. UTC

TG Therapeutics Inc. shares showed little change in after-market trading. The stock remains above its 20-day moving average, indicating stability.

28.08.2026 г., 19:51 ч. UTC

TG Therapeutics Inc shares are lower today, continuing a decline since Thursday's close. The stock remains above its 20-day moving average.

27.08.2026 г., 23:41 ч. UTC

TG Therapeutics Inc shares are lower in after-market hours, reflecting broader market declines. Economic indicators have not alleviated cautious sentiment amid inflation concerns.

26.08.2026 г., 19:16 ч. UTC

Social Media
News

TG Therapeutics raised its Briumvi revenue guidance to $890-$905 million, contributing to an upgrade of TGTX stock. Shares are trading roughly flat today.

25.08.2026 г., 23:36 ч. UTC

TG Therapeutics Inc. shares are trading roughly flat in after-market hours. The stock remains above its 20-day moving average and near its one-month trading range.

24.08.2026 г., 23:21 ч. UTC

TG Therapeutics Inc shares are higher in after-market hours, reflecting positive momentum following Monday's close, despite no specific news driving the movement.

22.08.2026 г., 00:02 ч. UTC

Social Media

TG Therapeutics shares are higher in after-market trading amid positive investor sentiment and discussions of significant price targets of $150 following recent market pressures.

21.08.2026 г., 23:01 ч. UTC

Social Media

TG Therapeutics Inc. is rising in after-market trading, fueled by positive investor sentiment and potential price targets between $150 and $200.

20.08.2026 г., 21:01 ч. UTC

TG Therapeutics Inc shares are higher in after-market hours, despite earlier declines. No specific news was identified to explain the price movement.

19.08.2026 г., 19:27 ч. UTC

TG Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday. The stock is trading above its 20-day moving average.

17.08.2026 г., 19:56 ч. UTC

Social Media
News

TG Therapeutics reported Q2 2026 revenue of $240.34 million and raised its full-year outlook to $950 million, driving shares higher during Monday's trading.

14.08.2026 г., 21:01 ч. UTC

TG Therapeutics Inc shares are lower in after-market trading amid broader market weakness. Disappointing U.S. retail sales data may be impacting investor sentiment.

13.08.2026 г., 20:02 ч. UTC

Social Media

TG Therapeutics Inc shares declined during Thursday's session, influenced by social media sentiment and prior bearish commentary from Bank of America.

10.08.2026 г., 19:16 ч. UTC

TG Therapeutics Inc shares are lower today amid a broader market decline, with U.S. stock futures dropping following a surprising labor market report.

7.08.2026 г., 23:16 ч. UTC

TG Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement, which may reflect broader market sentiment.

6.08.2026 г., 20:03 ч. UTC

News

TG Therapeutics is lower today, impacted by declines in the Biotechnology sector. The company reported higher revenue but noted a decrease in net income and EPS.

5.08.2026 г., 19:56 ч. UTC

Social Media

TG Therapeutics is higher as analysts project GAAP net income could exceed $350 million in 2027, driven by revenue growth and pipeline developments.

4.08.2026 г., 23:56 ч. UTC

TG Therapeutics Inc. shares are roughly flat in after-market trading. The price remains below its 20-day moving average, indicating ongoing weakness.

3.08.2026 г., 23:06 ч. UTC

Social Media

TG Therapeutics Inc. shares are higher in after-market trading following Q2 revenues of $236 million and ongoing positive sentiment from clinical trials.

31.07.2026 г., 23:16 ч. UTC

No specific news was identified for TG Therapeutics Inc. After-market trading remains routine, with the stock showing little change in value.

30.07.2026 г., 23:56 ч. UTC

TG Therapeutics Inc shares are lower in after-market hours, with no specific news identified for the decline amid broader market uncertainty over interest rates.

29.07.2026 г., 15:52 ч. UTC

Social Media
News

TG Therapeutics shares are lower amid negative sentiment following the announcement of a conference call to discuss second quarter results and future outlook.

28.07.2026 г., 19:56 ч. UTC

TG Therapeutics shares are lower today amid broader market declines and a significant drop in the Nikkei 225 Index, reflecting negative sentiment.

27.07.2026 г., 19:07 ч. UTC

Social Media

B. Riley raised its price target for TG Therapeutics to $86, citing strong demand for Briumvi and anticipated revenue growth. Shares are trading roughly flat.

24.07.2026 г., 23:21 ч. UTC

TG Therapeutics Inc shares are lower in after-market hours, reaching a significant decline and hitting the lowest point of the day. No specific news was identified.

23.07.2026 г., 23:22 ч. UTC

TG Therapeutics traded roughly flat in after-market hours, with minimal change since Thursday's close, oscillating within its one-month trading range.

Сравнение с други в отрасъла

Ценова промяна

TG Therapeutics Inc Прогноза

Ценова цел

By TipRanks

23.56% нагоре

12-месечна прогноза

Среден 69.17 USD  23.56%

Висок 86 USD

Нисък 21 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за TG Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

5

Купи

0

Задържане

1

Продай

Настроение

By Acuity

132 / 339 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat